Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

654

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
Atopic Dermatitis Eczema
Interventions
DRUG

Roflumilast Cream 0.15%

Roflumilast Cream 0.15% - Active

DRUG

Vehicle Cream

Cream - Vehicle

Trial Locations (49)

19073

Arcutis Clinical Site 35, Newtown Square

20850

Arcutis Clinical Site 36, Rockville

30328

Arcutis Clinical Site 26, Sandy Springs

32256

Arcutis Clinical Site 04, Jacksonville

33014

Arcutis Clinical Site 39, Miami Lakes

33134

Arcutis Clinical Site 30, Coral Gables

33162

Arcutis Clinical Site 38, North Miami Beach

33449

Arcutis Clinical Site 61, Wellington

33613

Arcutis Clinical Site 01, Tampa

33770

Arcutis Clinical Site 15, Largo

Arcutis Clinical Site 13, Rolling Meadows

36117

Arcutis Clinical Site 57, Montgomery

37130

Arcutis Clinical Site 31, Murfreesboro

40217

Arcutis Clinical Site 03, Louisville

46250

Arcutis Clinical Site 02, Indianapolis

47129

Arcutis Clinical Site 48, Clarksville

48202

Arcutis Clinical Site 37, Detroit

48326

Arcutis Clinical Site 55, Auburn Hills

48346

Arcutis Clinical Site 46, Clarkston

48706

Arcutis Clinical Site 54, Bay City

55112

Arcutis Clinical Site 10, New Brighton

72212

Arcutis Clinical Site 58, Little Rock

76011

Arcutis Clinical Site 19, Arlington

77030

Arcutis Clinical Site 27, Houston

77056

Arcutis Clinical Site 20, Houston

77401

Arcutis Clinical Site 43, Bellaire

78218

Arcutis Clinical Site 28, San Antonio

84095

Arcutis Clinical Site 21, South Jordan

85255

Arcutis Clinical Site 34, Scottsdale

89509

Arcutis Clinical Site 33, Reno

90056

Arcutis Clinical Site 52, Los Angeles

90212

Arcutis Clinical Site 40, Beverly Hills

91320

Arcutis Clinical Site 62, Thousand Oaks

92024

Arcutis Clinical Site 06, Encinitas

92123

Arcutis Clinical Site 05, San Diego

94132

Arcutis Clinical Site 08, San Francisco

97030

Arcutis Clinical Site 17, Gresham

97223

Arcutis Clinical Site 16, Portland

97239

Arcutis Clinical Site 14, Portland

99202

Arcutis Clinical Site 12, Spokane

08520

Arcutis Clinical Site 42, East Windsor

02919

Arcutis Clinical Site 101, Johnston

T2J 7E1

Arcutis Clinical Site 41, Calgary

E3B 1G9

Arcutis Clinical Site 29, Fredericton

L3P 1X3

Arcutis Clinical Site 11, Markham

L5H 1G9

Clinical Site 25, Mississauga

K9J 5K2

Arcutis Clinical Site 32, Peterborough

N8W 1E6

Arcutis Clinical Site 09, Windsor

H2X 2V1

Arcutis Clinical Site 24, Montreal

Sponsors
All Listed Sponsors
lead

Arcutis Biotherapeutics, Inc.

INDUSTRY

NCT04773587 - Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | Biotech Hunter | Biotech Hunter